Screening of Biomarkers and Related Mechanisms for RIX

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Nov 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called dry mouth, which many patients experience after undergoing treatments like radiotherapy for head and neck cancer. Dry mouth, or xerostomia, can make it difficult to chew and swallow, and can cause pain and discomfort in the mouth. The goal of this study is to find early signs, known as biomarkers, that can predict who might develop this condition. By understanding the causes better and identifying these biomarkers, researchers hope to intervene earlier, leading to improved treatment outcomes and a better quality of life for patients.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of head and neck cancer. You should be planning to receive treatment that includes radiotherapy, either alone or with other therapies. However, if you have a history of severe dry mouth before treatment, metastatic disease (cancer that has spread), or certain serious health issues, you may not be eligible. Participants will provide blood samples before and after their treatment, which will help researchers identify the biomarkers associated with dry mouth and test their effectiveness. If you choose to join, you will play an important role in helping doctors improve care for future patients dealing with the effects of cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of head and neck cancer;
• • Plan to undergo curative treatment with radiotherapy alone or in combination with synchronous chemotherapy, immunotherapy, or targeted therapy;
• • Age greater than or equal to 18 years old, Fully understand the purpose and significance of this study, voluntarily participate and sign an informed consent form.
• Exclusion Criteria:
• • Metastatic diseases;
• • History of head and neck radiotherapy;
• • Severe dry mouth before radiotherapy;
• • Suffering from advanced chronic diseases: heart failure - New York Heart Association functional classification III/IV, renal failure - estimated glomerular filtration rate under 30mL/min/1.73m2, liver failure - Child Pugh score C or D.